CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Quest PharmaTech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Quest PharmaTech Inc
8123 Roper Road NW
Phone: (780) 448-1400p:780 448-1400 EDMONTON, AB  T6E 6S4  Canada Ticker: QPTQPT

Business Summary
Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
10/31/20231/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board J. MarkLievonen 7/5/2021 7/19/2017
Chief Executive Officer, Director RagupathyMadiyalakan 1/1/2022 6/17/2004
Chief Financial Officer PierreVermette 1/18/2005 1/18/2005
Independent Director Shawn S.Lu 12/1/2015 12/1/2015
Independent Director JeffreyShon 7/5/2021 7/5/2021

Subsidiaries
Business Name Address City State/Province Country
Oncoquest, Inc. 8123 Roper Road NW Edmonton AB United States

Business Names
Business Name
ALPJF
Altachem Pharma Ltd.
Oncoquest, Inc.
QPT
Quest Pharmatech Ltd.

General Information
Outstanding Shares: 169,129,247 (As of 10/31/2023)
Stock Exchange: CVE
Fax Number: (780) 448-1400


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024